Colorectal screening looks for cancer before symptoms; surveillance follows a specific earlier finding or risk. Selected screening definition; Attributed surveillance scope. A stool screening result does not diagnose cancer or replace investigation of new symptoms. Selected result limitations. Confidence: high for these pathway distinctions; moderate for attributed specialist frameworks. No independently audited comparison of commercial tests or personal screening calendar is established.
- Routine screening, investigation of symptoms and surveillance after earlier findings answer different questions.
- FIT looks for blood in stool; a result needing further tests is not itself a cancer diagnosis.
- A reassuring screening result cannot rule out every cancer or justify ignoring new symptoms.
- Polyp pathology, colonic IBD, inherited risk and previous cancer may require distinct specialist plans.
- Keep the examination report, pending tissue results and written follow-up plan together; clarify who owns each step.
- Evidence summary
- What screening, diagnostic investigation and surveillance mean
- Polyps, bleeding and why one result cannot settle every question
- Colonoscopy, polyp removal and the specialist next step
- Risk reduction, food and supplement claims
- Surveillance after polyps, colonic IBD, inherited risk or cancer
- Symptoms needing assessment despite screening
- Procedure risks and medicines requiring a personal preparation plan
- Who needs additional planning and accessible information
- Results, pathology and a written follow-up plan
- Detection, patient outcomes and independent evidence limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical guidance, human outcome research and funding independence answer different questions. The guidance below explains care; it does not independently reproduce the trials behind a medicine or supplement.
| Claim / intervention | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Population screening and FIT | Selected national/programme explanations | Separate public accounts; exact authors, page allocation and original screening-trial receipts unclosed. | A sample result may lead to further assessment; no personal invitation calendar or independent assay ranking. |
| Polyp, IBD and post-cancer surveillance | Selected BSG specialist frameworks | Documented public/charitable support and relevant drug/device author ties; full society and underlying-study chains unclosed. | Use the actual specialist plan; hereditary risk has separate scope and no universal interval is supplied. |
| Colonoscopy and tissue results | Selected programme and dated national procedure sources | National public route does not clear every device, preparation product or cited harm study. | Discuss consent, pending pathology and follow-up ownership; no personal preparation regimen or outcome rate. |
| Symptoms and supplement safety | Current NHS urgency and dated NCCIH safety context | Public finance and gift permission separately traced; current contributor/source-study chains unclosed. | Assessment continues despite screening; no supplement replaces investigation or the agreed surveillance plan. |
What screening, diagnostic investigation and surveillance mean
Colorectal means the colon and rectum, the large bowel. NCI distinguishes tests offered before symptoms from clinical assessment of a current problem. Selected anatomy and screening scope. Ask which pathway an invitation or referral belongs to; the same test name can be used for different reasons.
The national NHS explains that FIT, or faecal immunochemical testing, checks a stool sample for blood. Further tests may be offered when blood is found. Selected FIT pathway. This measures a sign that needs interpretation, rather than looking directly at all bowel tissue.
BSGβs post-polyp and post-cancer framework addresses follow-up after removal, including who needs surveillance and when it can end. Selected framework scope. Ask whether your present plan follows a polyp, cancer treatment, inflammation or a hereditary risk; a population invitation is not a complete description of each pathway.
Polyps, bleeding and why one result cannot settle every question
Bowel polyps are small growths in the colon or rectum; some can lead to cancer. Selected dated anatomy. A removed growthβs laboratory report matters: ask what type was found and what its actual pathology means for follow-up, rather than treating every polyp as cancer.
Englandβs screening leaflet explains that a βno further testsβ result may mean no blood or an amount below the screening level. A lesion may be missed if it was not bleeding when sampled. Selected result limits. Do not convert a negative screening sample into a promise that every current symptom has been explained.
Ask the clinician what the result can and cannot establish. A sample result, examination finding and tissue diagnosis are different pieces of information. If a report is incomplete or the question has changed, request an explanation of the next assessment rather than trying to resolve uncertainty by repeatedly buying home kits.
Colonoscopy, polyp removal and the specialist next step
Englandβs colonoscopy leaflet describes review of a screening result, suitability, risks and comfort options before the examination. Colonoscopy looks inside the bowel and may allow a biopsy or removal of a polyp. Selected assessment and procedure roles. Ask what the proposed procedure is expected to answer and what alternatives can actually answer that question.
NCI lists stool-based tests, sigmoidoscopy, colonoscopy and CT-based virtual colonoscopy among screening approaches. Selected test categories. These are different procedures; the list is not an independent ranking or a claim that every option is locally offered or suitable.
Discuss the possible next step if the test is incomplete or finds an abnormality. Ask whether further tissue sampling, a specialist removal procedure or a different service could be required. Clarify what was consented to, what can be done during the examination and what would need a separate discussion.
Risk reduction, food and supplement claims
Current national NHS advice includes stopping smoking, remaining active, balanced eating and limiting alcohol and processed/red meat among risk-reduction measures. It also says prevention cannot be guaranteed. Selected current prevention context. These measures do not replace investigation, screening or an agreed surveillance plan.
NCCIH warns that supplements can interact with medicines and cause harm. Selected dated safety context. No supplement, detox, probiotic brand or βgut cleanseβ is independently established here to replace a screening pathway or remove a polyp.
Tell the team about restrictions, poor intake, difficulty obtaining food and products already used. Ask whether an identified nutritional need requires individual support. This guide gives no preventive supplement dose, colon-cleansing regimen or claim that symptoms improving on a diet establishes absence of cancer.
Surveillance after polyps, colonic IBD, inherited risk or cancer
BSGβs 2025 colonic-IBD framework notes that risk varies with disease extent, duration, inflammation and other factors, including primary sclerosing cholangitis. Not every person with IBD needs the same surveillance pathway. Selected risk-assessment framework. Ask the IBD team how the actual bowel involvement and earlier findings affect your plan.
The post-polyp/post-cancer framework explicitly excludes hereditary colorectal syndromes from its scope. Selected inherited-risk boundary. Current NHS information recognizes Lynch syndrome and familial adenomatous polyposis as distinct risk contexts. Selected inherited-risk context. Ask which specialist service coordinates that risk; do not copy a generic polyp calendar.
For previous cancer, ask how bowel surveillance fits the separate oncology follow-up. For a previous polyp, ask which tissue findings and completeness of removal determine the recommendation. This article supplies no polyp-count cutoff, gene-specific schedule or universal interval for restarting, repeating or stopping colonoscopy.
Symptoms needing assessment despite screening
Current NHS bowel-cancer guidance calls for assessment of unexplained bowel changes, rectal bleeding, abdominal symptoms or weight loss. These can have other causes, but need review. Selected current symptom assessment. Tell the clinician about the actual change even when a recent screening letter was reassuring.
That current source advises urgent help for black/dark-red stool or bloody diarrhoea, and emergency care for ongoing major rectal bleeding or large clots. Selected urgent and emergency categories. Use the equivalent local service outside the UK; no home waiting threshold is given.
The colonoscopy safety source identifies heavy or worsening bleeding, severe or worsening abdominal pain and fever/shivering after the procedure as reasons for urgent contact. Selected dated aftercare warning signs. Obtain the actual serviceβs written urgent route. Do not assume a possible complication can wait until a tissue-result appointment.
Procedure risks and medicines requiring a personal preparation plan
The national colonoscopy source identifies sedation reactions, bleeding and a bowel tear among consent risks. Selected dated consent context. Ask about the actual procedure, including planned removal or sampling, your health conditions and the limits of the examination; no risk rate or rarity reassurance is supplied.
NHS preparation information says to inform the hospital about pregnancy and medicines, and to use its individual instructions. Selected dated preparation roles. Bring prescriptions, anticoagulants, diabetes treatment and supplements to the actual assessment. Ask which prescriber resolves any proposed change.
The article provides no medicine pause, fasting interval, laxative dose or fluid target. If instructions conflict, ask the service and responsible prescriber to reconcile them in writing. An old leaflet, a different hospitalβs checklist or another personβs preparation cannot account for every condition and formulation.
Who needs additional planning and accessible information
The England screening leaflet offers support when a person has had surgery, has a stoma or is unsure how to use the kit. Selected access and suitability questions. Ask the screening service what applies to your actual anatomy rather than adapting an ordinary sample instruction on your own.
Tell the team about previous difficult examinations, allergies, pregnancy, major heart/lung/kidney illness, mobility needs or distress about the procedure. Request an individualized discussion of consent, comfort and support. This guide gives no blanket eligibility clearance or instruction to cancel an established surveillance plan.
Ask for translated, easy-read or accessible material, and discuss who may help you understand or communicate the decision. Confirm local invitation rules with the programme; country, age and risk policies can differ. A missed invitation, incorrect address or transfer between services should be raised with the team rather than treated as proof that screening is unnecessary.
Results, pathology and a written follow-up plan
The NHS results source distinguishes no polyp/cancer found, removed growths requiring tissue interpretation, cancer and other bowel conditions. Selected dated result categories. Ask which findings are final and which are still waiting for laboratory review; the spoken examination result may not be the complete report.
Request a copy of the procedure and pathology reports, the recommended next step and the person responsible for arranging it. Ask whether the examination was complete, whether any finding needs further assessment and how the plan will be communicated to your GP or relevant specialist.
Keep routine population screening separate from a specialistβs surveillance arrangement. If invitations overlap, ask the services to explain the current pathway rather than dropping one yourself. Clarify whom to contact for missing results or a delayed appointment, and obtain assessment for changed symptoms while follow-up is being organized.
Detection, patient outcomes and independent evidence limits
Finding blood, detecting a polyp, recognizing tissue changes and preventing a cancer death are different outcomes. A commercial testβs detection claim does not by itself establish the full benefit, false-positive burden or consequences of follow-up. Ask which outcome and comparison the evidence actually measured.
No commercial assay, artificial-intelligence system, device or supplement is ranked here. Animal or cell mechanisms do not establish a human screening benefit. A society framework with transparent methods can explain care while its supporting trials still need their own complete financial audit before a manufacturer-funded result enters an independent verdict.
Funding and source roles
Research funding at a glance
22 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this articleβs source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
National NHS education, England programme leaflets and BSG frameworks are separate sources. Institutional public funding is documented below, while BSGβs relevant author interests are recorded alongside its methods and production statements. Neither route establishes the allocation to every original study.
NCIβs public budget, gift authority and editorial model are separate from its clinical summary. PDQ editorial separation does not clear every external member or sponsored trial. UK and US source settings may differ from local practice. Several national 2022/2023 procedure pages are dated and past scheduled review; exact current personal instructions must come from the service.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| National NHS bowel cancer screening, October 2024; January 2026 media review | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | B provisional β actual dated national patient body read; public care accountability and clinical checking favor accuracy, while simplification and full contributor/trial finance remain gaps. |
| England public screening decision leaflet, June 23, 2025 | Separate NHS England own current accounts. Exact programme-leaflet allocation, authors and underlying-study receipts unclosed. National NHS website advertising policy is not assigned to every GOV.UK publication or provider. | United Kingdom; England screening programme, hosted on GOV.UK; national NHS England contact separately traced in Leeds. | Tier 2 public clinical context, provisional. | C provisional β actual selected original read; public and clinical accountability favors accuracy, while simplified programme advice and complete contributor/source-study finance remain gaps. No independent outcome estimate. |
| England screening colonoscopy leaflet, June 23, 2025 | Separate NHS England own current accounts. Exact programme-leaflet allocation, authors and underlying-study receipts unclosed. National NHS website advertising policy is not assigned to every GOV.UK publication or provider. | United Kingdom; England screening programme, hosted on GOV.UK; national NHS England contact separately traced in Leeds. | Tier 2 public clinical context, provisional. | C provisional β actual selected original read; public and clinical accountability favors accuracy, while simplified programme advice and complete contributor/source-study finance remain gaps. No independent outcome estimate. |
| National NHS bowel polyps, July 28, 2023; review due passed | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | C provisional β actual dated selected body read; scheduled review passed. Public clinical accountability favors accuracy, while dated instructions, simplification and unclosed contributor/trial finance remain. No personal preparation, waiting or recovery schedule. |
| National NHS bowel cancer causes/risk, September 4, 2026 | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | B provisional β actual dated national patient body read; public care accountability and clinical checking favor accuracy, while simplification and full contributor/trial finance remain gaps. |
| National NHS bowel cancer symptoms, September 4, 2026 | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | B provisional β actual dated national patient body read; public care accountability and clinical checking favor accuracy, while simplification and full contributor/trial finance remain gaps. |
| National NHS colonoscopy preparation, November 14, 2022; review due passed | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | C provisional β actual dated selected body read; scheduled review passed. Public clinical accountability favors accuracy, while dated instructions, simplification and unclosed contributor/trial finance remain. No personal preparation, waiting or recovery schedule. |
| National NHS colonoscopy day and safety, November 14, 2022; review due passed | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | C provisional β actual dated selected body read; scheduled review passed. Public clinical accountability favors accuracy, while dated instructions, simplification and unclosed contributor/trial finance remain. No personal preparation, waiting or recovery schedule. |
| National NHS colonoscopy results, November 14, 2022; review due passed | See separate national accounts and website funding policy. Individual page allocation, external expert and original-study interests unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 2 public clinical context, provisional. | C provisional β actual dated selected body read; scheduled review passed. Public clinical accountability favors accuracy, while dated instructions, simplification and unclosed contributor/trial finance remain. No personal preparation, waiting or recovery schedule. |
| Original BSG colonic IBD surveillance guideline 2025, full 34-page | Original acknowledges public/charitable author support and no other manuscript-development funds. East reports Exact Sciences/Cosmo/Satisfai advisory roles and Satisfai shares; Iacucci Olympus/Pentax grants or materials, among other author drug/device ties. Separate society industry route. Complete amounts, author institutional income and source-trial chains unclosed. | United Kingdom; BSG London contact separately traced. Original authors report UK institutional affiliations; complete individual and backer jurisdictions unclosed. | Tier 3 professional guideline with relevant disclosed commercial author interests. | C provisional β actual selected full original and declarations read; specialist/method scrutiny favors accuracy, while known commercial interests, dated evidence and incomplete original-study finance remain. Attributed framework, no independent device or medicine advantage. |
| Original BSG/ACPGBI/PHE post-polypectomy/post-cancer guideline 2020, full 23-page | Original reports PHE evidence-synthesis/administrative/meeting funding and BSG support. East, Rees, Rutter and Tolan disclose relevant device/diagnostic company advisory, grant, consulting or speaking relationships. Separate society route. Complete ACPGBI, author/backer and original-study allocations unclosed. | United Kingdom; BSG London contact separately traced. Original authors report UK institutional affiliations; complete individual and backer jurisdictions unclosed. | Tier 3 professional guideline with relevant disclosed commercial author interests. | C provisional β actual selected full original and declarations read; specialist/method scrutiny favors accuracy, while known commercial interests, dated evidence and incomplete original-study finance remain. Attributed framework, no independent device or medicine advantage. |
| NCI PDQ colorectal screening patient summary, May 2, 2025 | Separate public budget original, gift authority and PDQ editorial model. Exact page, external expert and supporting-study finance unclosed; editorial separation does not clear sponsored trials. | United States; NCI/NIH/HHS, Bethesda/Rockville, Maryland; own communications-office location separately traced. Complete external editorial-member/backer jurisdictions unclosed. | Tier 2 public clinical context, provisional. | C provisional β actual selected original read; public and clinical accountability favors accuracy, while simplified programme advice and complete contributor/source-study finance remain gaps. No independent outcome estimate. |
| NCCIH supplement safety, January 2019; selected safety context only | Separate NCCIH historical public appropriations and Gift Fund authority. Current donor/page allocations and complete contributor/source-study chains unclosed. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 2 public safety context, provisional. | C provisional β actual selected safety original read; public scientific accountability favors accuracy, while dated summaries and unclosed author/study finance limit use. No independent efficacy conclusion. |
| BSG own industry-partnership route and London contact | Actual own page describes industry partnerships supporting scientific/educational work and gives London contact. Full 2024 audited-report retrieval failed; revenue amounts, complete named backers and individual page/study allocations unclosed. | United Kingdom; BSG own contact3 St Andrews Place, London. Individual guideline authors and partner jurisdictions not fully traced. | Tier 3 institutional financial/contact self-disclosure. | C provisional β actual partnership route read, full ledger access gap. Professional reputation and sponsorship incentives remain; financial context only. |
| NCI own budget explanation, May 14, 2026; enacted FY2026 separately identified | Actual May 2026 original distinguishes congressional enacted FY2026 appropriation from future budget requests and previous-year spending. No exact screening-summary allocation or complete current donor ledger verified. | United States; NCI/NIH/HHS, Bethesda/Rockville, Maryland; own communications-office location separately traced. Complete external editorial-member/backer jurisdictions unclosed. | Tier 3 institutional financial/process/contact self-report. | B provisional for explicitly dated original provenance; public reporting favors accuracy, while institutional priorities and incomplete current donor/page allocations remain. Financial context only. |
| NCI own gift agreement authority, April 2018, full 4-page | Actual April 2018 four-page original allows institutional monetary/nonmonetary conditional/unconditional gifts, reviewed through legal and ethics processes. Permission is not a named receipt, current donor amount or page payment. | United States; NCI/NIH/HHS, Bethesda/Rockville, Maryland; own communications-office location separately traced. Complete external editorial-member/backer jurisdictions unclosed. | Tier 3 institutional financial/process/contact self-report. | B provisional for explicitly dated original provenance; public reporting favors accuracy, while institutional priorities and incomplete current donor/page allocations remain. Financial context only. |
| NCI own PDQ editorial policy, November 2022 | Actual November 2022 policy describes editorial separation, small honoraria/travel for nongovernment members and recusal declarations, but does not request specific conflict disclosures. This is not full individual or supporting-trial financial clearance. | United States; NCI/NIH/HHS, Bethesda/Rockville, Maryland; own communications-office location separately traced. Complete external editorial-member/backer jurisdictions unclosed. | Tier 3 institutional financial/process/contact self-report. | B provisional for explicitly dated original provenance; public reporting favors accuracy, while institutional priorities and incomplete current donor/page allocations remain. Financial context only. |
| NCI own communications-office contact/location | Actual own communications-office contact identifies Bethesda, Maryland. Location establishes institutional jurisdiction, not contributor, donor or screening-trial finance. | United States; NCI/NIH/HHS, Bethesda/Rockville, Maryland; own communications-office location separately traced. Complete external editorial-member/backer jurisdictions unclosed. | Tier 3 institutional financial/process/contact self-report. | B provisional for explicitly dated original provenance; public reporting favors accuracy, while institutional priorities and incomplete current donor/page allocations remain. Financial context only. |
| NHS England own 2025β2026 audited accounts | Own 2025β2026 audited accounts identify DHSC grant-in-aid as principal finance, with services, research/training and other consolidated income. Parent and consolidated accounts differ. Exact website-page allocation unclosed. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| National NHS website content and funding policy, 2022 | Own 2022 policy says DHSC funds the national website, which rejects advertising/corporate sponsorship and requires staff/outside-agent interest reporting. This does not certify each supporting study or hospitalβs finances. | United Kingdom; national NHS England information, registered contact Leeds; individual provider finances separate. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| NCCIH actual appropriation history, through FY2024 | Own appropriation history documents congressional finance through FY2024; not a current enacted 2026 amount or page budget. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
| NCCIH separate conditional/unconditional Gift Fund authority | Own authority permits conditional and unconditional gifts/bequests in a fund separate from appropriation; operating costs from appropriation. Complete current donor ledger and clinical-page allocation unclosed. | United States; NIH/HHS NCCIH, actual contact Bethesda, Maryland. | Tier 3 institutional financial/contact self-disclosure. | B provisional for explicitly dated institutional provenance. Statutory/public scrutiny favors accuracy; institutional reporting incentives and allocation gaps remain. Financial context only. |
Frequently asked questions
Does a FIT result needing further tests mean cancer? No; blood has other possible causes and requires the recommended assessment. Selected result distinction.
Can a reassuring screening result explain new symptoms? No. Obtain assessment for a new change or continuing concern. Current assessment advice.
Does every removed polyp need the same follow-up? Ask how the actual findings and specialist plan determine the next step; no universal calendar is provided.
Is ordinary screening enough for colonic IBD or inherited risk? Ask the relevant specialist which pathway applies. A population invitation alone does not define the entire plan.
Can a supplement replace screening or surveillance? No independently cleared substitution is established here.
What should I keep after colonoscopy? The examination and tissue reports, written follow-up responsibility, and the actual urgent-contact instructions.
Sources and funding notes
Actually opened national NHS screening body, current September 2026 bowel symptom/risk bodies, dated July 2023 polyp and November 2022 colonoscopy preparation/day/results bodies. Passed procedure-page review dates are explicit. England June 2025 decision/colonoscopy originals actually read; more precise sub-threshold FIT wording used, no older symptom waiting rule adopted. Full BSG2025 IBD-surveillance34p and 2020 post-polyp/post-cancer23p originals opened; selected scope/risk passages and full funding/interest paragraphs read. Known relevant commercial authors are Tier3/C; no trial estimate, assay advantage, drug chemoprevention or personal surveillance interval adopted. NCI May 2025 PDQ selected body plus actual May 2026 budget, April 2018 four-page gift authority, November 2022 editorial policy and own office contact read. National accounts/policy, BSG industry model and NCCIH historical appropriation/gift originals separately checked. Complete individual contributor, donor and supporting-study financial chains remain unclosed. No personal preparation, medicine pause, gene/polyp threshold, symptom wait, eligibility calendar, risk rate, recovery guarantee or commercial product verdict supplied.
- National NHS bowel cancer screening, October 2024; January 2026 media review β Selected FIT roles and result limits; no programme age/calendar or sensitivity estimate
- England public screening decision leaflet, June 23, 2025 β Selected negative-result interpretation and access questions; outcome rates, personal sample timing and symptom waiting rule excluded
- England screening colonoscopy leaflet, June 23, 2025 β Selected consent, suitability and biopsy/removal roles; risk rates, recovery calendar and universal pain reassurance excluded
- National NHS bowel polyps, July 28, 2023; review due passed β Selected dated anatomy only; no progression probability
- National NHS bowel cancer causes/risk, September 4, 2026 β Selected current risk/prevention and inherited-condition context; no dose, numeric target or guaranteed prevention
- National NHS bowel cancer symptoms, September 4, 2026 β Selected current symptom and urgent categories; no home triage or waiting period
- National NHS colonoscopy preparation, November 14, 2022; review due passed β Selected dated service-instruction and disclosure roles; all preparation doses/calendar and fluid rules excluded
- National NHS colonoscopy day and safety, November 14, 2022; review due passed β Selected dated consent risks and urgent warnings; rarity, driving duration and painless-procedure reassurance excluded
- National NHS colonoscopy results, November 14, 2022; review due passed β Selected dated final/pending result distinction; response deadlines and guaranteed benign outcome excluded
- Original BSG colonic IBD surveillance guideline 2025, full 34-page β Selected colonic-IBD risk/MDT scope, not a personal interval, drug prevention or assay advantage
- Original BSG/ACPGBI/PHE post-polypectomy/post-cancer guideline 2020, full 23-page β Selected adult post-polyp/post-cancer and hereditary exclusion scopes; no count, size or calendar rule
- NCI PDQ colorectal screening patient summary, May 2, 2025 β Selected screening definition/anatomy/test categories; no independent comparative efficacy, screening age or mortality estimate
- NCCIH supplement safety, January 2019; selected safety context only β Selected generic supplement safety; no screening substitution evidence
- BSG own industry-partnership route and London contact β Separate actual industry-partnership model; full current audited ledger unclosed
- NCI own budget explanation, May 14, 2026; enacted FY2026 separately identified β Separate actual institutional appropriation explanation, not source-page funding
- NCI own gift agreement authority, April 2018, full 4-page β Separate actual institutional gift permission, not named receipts
- NCI own PDQ editorial policy, November 2022 β Separate dated editorial model and disclosure limits
- NCI own communications-office contact/location β Separate actual institutional location
- NHS England own 2025β2026 audited accounts β Separate current national audited finances
- National NHS website content and funding policy, 2022 β Separate dated national-website funding/editorial policy, not provider or all GOV.UK finance
- NCCIH actual appropriation history, through FY2024 β Separate historical appropriation report
- NCCIH separate conditional/unconditional Gift Fund authority β Separate gift authority, not current donor allocation
Educational information reviewed 4 October 2026. This guide supports an informed clinical discussion; it does not diagnose an individual or provide a personal treatment regimen.
Have a question β or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.